University of Oxford

AN2 Therapeutics completed a 200-patient observational study in acute melioidosis, revealing a striking mortality rate of nearly 40% by Day 90 despite standard of care treatment.

University of Oxford researchers have developed a programmable microcapsule delivery system that enables complete malaria vaccination in a single injection, eliminating the need for booster visits.

Llusern Scientific has received ISO 13485 certification for its Lodestar DX testing system, a rapid molecular diagnostic platform that delivers lab-accurate UTI results in approximately 30 minutes.

The University of Oxford and ReciBioPharm have expanded their collaboration to manufacture two blood-stage malaria vaccine candidates, R78C and RH5.1, for Phase 1/2 clinical trials.

LivaNova's comprehensive CORE-VNS study of over 800 patients worldwide demonstrates sustained effectiveness of VNS Therapy for drug-resistant epilepsy over 36 months.

A groundbreaking University of Oxford study reveals that prior cytomegalovirus (CMV) infection improves melanoma patients' response to single-drug PD-1 immunotherapy while reducing severe side effects.

Circle Pharma will present late-breaking data at AACR 2025 showing how their novel cyclin A/B RxL inhibitors disrupt DNA repair pathways and affect mitotic progression in E2F-high cancers.

Nearly half of young adults successfully quit vaping after three months using a combination of phone-based coaching, health apps, and nicotine replacement therapy, according to new research published in the American Journal of Preventive Medicine.

Infinitopes has received UK MHRA approval for a first-in-human Phase I/IIa clinical trial of ITOP1, an 'off-the-shelf' precision cancer vaccine designed to prevent recurrence in patients with surgically resectable oesophageal adenocarcinoma.

Two recent studies reveal that ezogabine, an FDA-approved epilepsy medication, may effectively treat depression by normalizing hyperactivity in the brain's reward circuitry through KCNQ potassium channel modulation.